searchspell:azntaccorrected for zantac
Ranitidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It is currently marketed by GlaxoSmithKline under the trade name Zantac. Clinical useMain article: H2-receptor antagonist Certain preparations of ranitidine are available over the counter (OTC) in various countries. In the United States, 75 mg and 150 mg tablets are available OTC. In Australia, small packs of 150 mg and 300 mg tablets are Schedule 2 Pharmacy Medicines. Larger doses and pack sizes still require a prescription. Outside of the United States, ranitidine is combined with bismuth (which acts as a mild antibiotic) as a citrate salt (ranitidine bismuth citrate, Tritec®), to treat Helicobacter pylori infections. This combination is usually given with clarithromycin, another antibiotic. History and developmentRanitidine was developed by Glaxo (now GlaxoSmithKline) in an effort to match the success of Smith, Kline & French (also now GlaxoSmithKline) with the first histamine H2-receptor antagonist cimetidine. Ranitidine was the result of a rational drug-design process utilising the, by then, fairly refined model of the histamine H2-receptor and quantitative structure-activity relationships (QSAR). Glaxo refined the model further by replacing the imidazole-ring of cimetidine with a furan-ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and ten times the activity of cimetidine. Ranitidine was introduced in 1981 and was the world's biggest-selling prescription drug by 1988. It has since largely been superseded by the even more effective proton pump inhibitors, with omeprazole becoming the biggest-selling drug for many years. Most likely you found this site by searching for azntac, but it is probable that you were really looking for information on zantac instead. The goal of searchspell is to direct the 10 to 20% of all internet queries that contain variant spellings to the resources they were really looking for; in this case "zantac" resources. If you believe the information on this site is in error, please contact us at mistype@gmail.com to provide details of the misinformation. If you are interested in adding to the content of this site, or if you are interested in supporting the efforts of misytped.info by placing your product information on all of the variant zantac pages, please contact mistype@gmail.com for details. This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "zantac".
| ||||||||||||||||||||||||